Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK

Clinical Obesity

Volumn 8, Issue 3, 2018, Pages 211-225

  Wilding, J P H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anti obesity medications; obesity; weight management

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; LIRAGLUTIDE; AMFEBUTAMONE; NALTREXONE;

BARIATRIC SURGERY; BODY MASS; BODY WEIGHT CONTROL; BODY WEIGHT LOSS; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLINICAL PRACTICE; COMORBIDITY; EPIDEMIC; FINANCIAL MANAGEMENT; HEALTH HAZARD; HEALTH PROGRAM; HEALTH STATUS; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SPECIALIST; OBESITY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; RISK REDUCTION; UNITED KINGDOM; WORKLOAD; BODY WEIGHT MAINTENANCE; HEALTH SERVICE; LIFESTYLE; NATIONAL HEALTH SERVICE; PRIMARY HEALTH CARE; SPECIALIZATION; WEIGHT LOSS PROGRAM;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BODY WEIGHT MAINTENANCE; BUPROPION; HEALTH SERVICES; HUMANS; LIFE STYLE; LIRAGLUTIDE; NALTREXONE; OBESITY; PRIMARY HEALTH CARE; SPECIALIZATION; STATE MEDICINE; UNITED KINGDOM; WEIGHT LOSS; WEIGHT REDUCTION PROGRAMS;

EID: 85053887274     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12248     Document Type: Review

References (77)

1. OECD. Organisation for Economic Co-operation and Development Health Statistics: Obesity update, 2017. URL http://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf (accessed 20 December 2017).
2. McKinsey Global Institute. Overcoming Obesity: An Initial Economic Crisis. McKinsey, 2014.
3. National Institute for Health and Care Excellence (NICE). Obesity: identification, assessment and management (CG189), 2014. URL https://www.nice.org.uk/guidance/cg189/resources/obesity-identification-assessment-and-management-pdf-35109821097925 (accessed 20 December 2017).
4. National Institute for Health and Care Excellence (NICE). Weight management: lifestyle services for overweight or obese adults (PH53), 2014. URL https://www.nice.org.uk/guidance/ph53/resources/weight-management-lifestyle-services-for-overweight-or-obese-adults-1996416726469 (accessed 20 December 2017).
5. Scottish Intercollegiate Guidelines Network (SIGN). Management of obesity: a national clinical guideline, 2010. URL http://www.sign.ac.uk/assets/sign115.pdf (accessed 20 December 2017).
6. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation 2014; 129: S102–S138.
7. Mann T, Tomiyama AJ, Westling E et al. Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol 2007; 62: 220–233.
8. Hughes CA. The rewards and challenges of setting up a tier 3 adult weight management service in primary care. Br J Obes 2015; 1: 25–31.
9. ® (rimonabant) 2009. URL http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf (accessed 20 December 2017).
10. EMA. Questions and answers on the suspension of medicines containing sibutramine, 2010. URL http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf (accessed 20 December 2017).
11. Douglas IJ, Bhaskaran K, Batterham RL, Smeeth L. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. Br J Clin Pharmacol 2015; 79: 1020–1027.
12. Maahs D, de Serna DG, Kolotkin RL et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006; 12: 18–28.
13. NHS. Health Survey for England (NHS Digital), 2015. URL http://www.content.digital.nhs.uk/catalogue/PUB22610/HSE2015-Sum-bklt.pdf (accessed 20 December 2017).
14. Health Survey Northern Ireland. 2015/2016 [WWW document]. URL https://www.health-ni.gov.uk/sites/default/files/publications/health/hsni-first-results-15-16.pdf (accessed 20 December 2017).
15. Scottish Health Survey. 2015 [WWW document]. URL http://www.gov.scot/Publications/2016/09/2764 (accessed 20 December 2017).
16. Welsh Health Survey. 2015 [WWW document]. URL http://gov.wales/statistics-and-research/welsh-health-survey/?lang=en (accessed 20 December 2017).
17. Baker C. Obesity statistics: briefing paper. House of Commons Library 2017; 3336: 1–20.
18. Yuen MS, Lui DT, Kaplan LM et al. A systematic review and evaluation of current evidence reveals 195 obesity-associated disorders (OBAD). Obesity Week; New Orleans, Louisiana, US (Poster T-P-3166) 2016.
19. Must A, Spadano J, Coakley EH et al. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523–1529.
20. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010; 89: 309–319.
21. Marathe PH, Gao HX, Close KL. American diabetes association standards of medical Care in Diabetes 2017. J Diabetes 2017; 9: 320–324.
22. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815–825.
23. (BOMSS) BOaMSS. Patient access to bariatric surgery 2017. URL http://www.bomss.org.uk/wp-content/uploads/2017/03/RCS-and-BOMSS-Bariatric-report-2017.pdf (accessed 20 December 2017).
24. Jennings A, Hughes CA, Kumaravel B et al. Evaluation of a multidisciplinary tier 3 weight management service for adults with morbid obesity, or obesity and comorbidities, based in primary care. Clin Obes 2014; 4: 254–266.
25. Morrison DS, Boyle S, Morrison C et al. Evaluation of the first phase of a specialist weight management programme in the UK National Health Service: prospective cohort study. Public Health Nutr 2012; 15: 28–38.
26. Senior L, Carter D, Capehorn M. Service evaluation of the Rotherham Institute for Obesity and comparison of 2010 and 2011 data. Obes Facts 2013; 6: 49–230 (Poster 084).
27. Ahern AL, Wheeler GM, Aveyard P et al. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. Lancet 2017; 389: 2214–2225.
28. National Institute for Health and Care Excellence (NICE). Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children, 2006. URL https://www.nice.org.uk/guidance/cg189/evidence/obesity-update-appendix-p-6960327450 (accessed 20 December 2017).
29. Dixon KJ, Shcherba S, Kipping RR. Weight loss from three commercial providers of NHS primary care slimming on referral in North Somerset: service evaluation. J Public Health (Oxf) 2012; 34: 555–561.
30. Holzapfel C, Cresswell L, Ahern AL et al. The challenge of a 2-year follow-up after intervention for weight loss in primary care. Int J Obes (Lond) 2014; 38: 806–811.
31. Counterweight Project Team. Evaluation of the counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract 2008; 58: 548–554.
32. RIO. How can I be referred (Rotherham Institute for Obesity), 2017. URL http://www.rotherhaminstituteforobesity.co.uk/How-can-I-be-referred.html (accessed 20 December 2017).
33. Upton M. Huge funding blow for Rotherham Insitute for obesity. Rotherham Advertiser 2017 (accessed 20 December 2017).
34. Steele T, Narayanan RP, James M et al. Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement. Clin Obes 2017; 7: 368–376.
35. National Institute for Health and Care Excellence (NICE). Accessing NHS care and treatment recommended by NICE, 2014. URL https://www.nice.org.uk/corporate/ecd4/resources/accessing-nhs-care-and-treatment-recommended-by-nice-pdf-1124012418757 (accessed 20 December 2017).
36. Lean ME, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes (Lond) 2016; 40: 622–632.
37. Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr 2008; 87: 1238–1246.
38. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623–1630.
39. Geldszus R, Mayr B, Horn R et al. Serum leptin and weight reduction in female obesity. Eur J Endocrinol 1996; 135: 659–662.
40. Keim NL, Stern JS, Havel PJ. Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women. Am J Clin Nutr 1998; 68: 794–801.
41. Leibel RL, Hirsch J. Diminished energy requirements in reduced-obese patients. Metabolism 1984; 33: 164–170.
42. Sumithran P, Prendergast LA, Delbridge E et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597–1604.
43. Townshend T, Lake A. Obesogenic environments: current evidence of the built and food environments. Perspect Public Health 2017; 137: 38–44.
44. ® (orlistat 120 mg). Summary of Product Characteristics, 1998. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000154/WC500058428.pdf (accessed 5 April 2017).
45. US Food and Drug Administration (FDA). FDA drugs. URL www.fda.gov/Drugs/default.htm (accessed 20 December 2017).
46. EMA. EMA medicines, 2015. URL www.ema.europa.eu/ (accessed 20 December 2017).
47. ® (orlistat 60 mg). Summary of Product Characteristics, 2007. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000854/WC500024120.pdf (accessed 20 December 2017).
48. EMA. Public statement on Acomplia (rimonabant): Withdrawal of marketing authorisation in the European Union (EMEA/39457/2009), 2009. URL http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf (accessed 20 December 2017)].
49. EMA. Mysimba SmPC. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003687/WC500185580.pdf (accessed 12 February 2018)].
50. EMA. Saxenda SmPC. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf (accessed 12 February 2018).
51. National Institute for Health and Care Excellence (NICE). Obesity, overweight with risk factors - naltrexone-bupropion (prolonged release) [ID757], In Press 2017. URL https://www.nice.org.uk/guidance/indevelopment/gid-tag486 (accessed 20 December 2017).
52. EMA. Qsiva: Assessment report. Procedure No. EMEA/H/C/002350/0000. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002350/WC500144300.pdf (accessed 12 February 2018).
53. EMA. Belviq: Assessment report. Procedure No. EMEA/H/C/002597. URL http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002597/WC500148196.pdf (accessed 12 February 2018)].
54. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–2125.
55. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.
56. Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011; 10: 495–506.
57. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 2006; 1: e9.
58. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595–605.
59. James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905–917.
60. Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011; 2: 19–23.
61. Apovian CM, Aronne L, Rubino D et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md) 2013; 21: 935–943.
62. Hollander P, Gupta AK, Plodkowski R et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022–4029.
63. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med 2015; 373: 11–22.
64. le Roux CW, Astrup A, Fujioka K et al. et al, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389: 1399–1409.
65. Davies MJ, Bergenstal R, Bode B et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015; 314: 687–699.
66. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443–1451.
67. Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016; 40: 1310–1319.
68. Bluher M, Hermansen K, Greenway F et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia 2015; 58: S310 (abstract 645).
69. National Obesity Observatory. Standard evaluation framework for weight management interventions, 2009. URL http://webarchive.nationalarchives.gov.uk/20160805121933/http://www.noo.org.uk/core/frameworks/SEF (accessed 20 December 2017).
70. NHS. NHS Digital: Methodology document, 2017. URL https://digital.nhs.uk/catalogue/PUB30142 (accessed 20 December 2017).
71. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in Medical Expenditures Associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics 2015; 33: 707–722.
72. NHS. NHS Diabetes Prevention Programme and weight management services: eligibility criteria, 2016. URL https://www.england.nhs.uk/wp-content/uploads/2016/07/dpp-wm-service.pdf (accessed 20 December 2017).
73. Piper C, Marossy A, Griffiths Z, Adegboye A. Evaluation of a type 2 diabetes prevention program using a commercial weight management provider for nondiabetic hyperglycemic patients referred by primary care in the UK. BMJ Open Diab Res Care 2017; 5: e000418.
74. NHS. NHS Diabetes Prevention Programme (NHS DPP), 2016. URL https://www.england.nhs.uk/ourwork/qual-clin-lead/diabetes-prevention/ (accessed 20 December 2017).
75. Caterson ID, Finer N, Coutinho W et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523–530.
76. Lean ME, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–551.
77. O'Neill PM, Birkenfeld AL, McGowan B et al. A randomised, phase II, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes. Endocr Rev 2018; 39:(Suppl): OR12–OR15.